Get access to our best features
Get access to our best features
Published 2 months ago

Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial

Summary by Ground News
Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday. The company released data from a late-stage study of Filspari in IgA nephropathy. In a head-to-head study versus irbesartan, FilsPari fell short of producing a statistically significant difference by one measure of kidney function.
More
Filters

2 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics